

DAFTAR PUSTAKA

- Adeolu, M., Alnajar, S., Naushad, S., & Gupta, R.S., 2016. Genome-based phylogeny and taxonomy of the ‘Enterobacteriales’: Proposal for enterobacterales ord. nov. divided into the families Enterobacteriaceae, Erwiniaceae fam. nov., Pectobacteriaceae fam. nov., Yersiniaceae fam. nov., Hafniaceae fam. nov., Morgane. *Int. J. Syst. Evol. Microbiol.* 66(12): 5575–5599.
- Agustina, D., Jiwangga, B., Nurdian, Y., Suswati, E., Mufida, D.C., *et al.*, 2023. Effect of exposure Pili Protein 65,5 kDa. *Biomol. Heal. Sci. J.* 6(1): 64–69.
- Ahn, J.Y., Ahn, S.M., Kim, J.H., Jeong, S.J., Ku, N.S., *et al.*, 2023. Clinical Characteristics and Associated Factors for Mortality in Patients with Carbapenem-Resistant Enterobacteriaceae Bloodstream Infection. *MDPI.* 11:1121-1132.
- Ahn, J.Y., Ann, H.W., Jeon, Y., Ahn, M.Y., Oh, D.H., *et al.*, 2017. The impact of production of extended- spectrum β -lactamases on the 28-day mortality rate of patients with *Proteus mirabilis* bacteremia in Korea *BMC Infect. Dis.* 17:327-339.
- Aiesh, B.M., Maali, Y., Qandeel, F., Omarya, S., Taha, S.A., *et al.*, 2023. Epidemiology and clinical characteristics of patients with carbapenem-resistant enterobacterales infections: experience from a large tertiary care center in a developing country. *BMC Infect. Dis.* 23: 1–10.
- Aiesh, B.M., Natsheh, M., Amar, M., AbuTaha, S., Qadi, M., *et al.*, 2024. Epidemiology and clinical characteristics of patients with healthcare-acquired multidrug-resistant Gram-negative bacilli: a retrospective study from a tertiary care hospital. *Sci. Rep.* 14(1): 1–11.
- Al Mamari, A.M.K., Al Jabri, Z., Sami, H., Rizvi, S.G.A., Chan, M.F., *et al.*, 2023. Evaluation of six commercial and in-house phenotypic tests for detection of AmpC β -lactamases: is routine detection possible? *JAC-Antimicrobial Resist.* 5(5): 1-11.
- Aljohni, M.S., Harun-Ur-Rashid, M., & Selim, S., 2025. Emerging threats: Antimicrobial resistance in extended-spectrum beta-lactamase and carbapenem-resistant *Escherichia coli*. *Microb. Pathog.* 200: 1-21.
- Almohareb, S.N., Aldairem, A., Alsuhebany, N., Alshaya, O.A., Aljatli, D., *et al.*, 2024. Effectiveness of oral antibiotics in managing extended-spectrum B-lactamase urinary tract infections: A retrospective analysis. *SAGE Open Med.* 12:1-7.

- Alowais, S.A., Aldairem, A., Almohareb, S.N., Alsaeed, Y., Aldugiem, R., *et al.*, 2025. Characteristics and Outcomes of Patients Treated with Carbapenem Versus Non-carbapenem Therapy for AmpC-Producing Enterobacterales Bacteremia: A Retrospective Study. *Infect. Dis. Ther.* 14(5): 1061–1074.
- Alsamawi, M., Joudeh, A.I., Eldeeb, Y., Al-Dahshan, A., Khan, F., *et al.*, 2022. Epidemiology of extended-spectrum beta-lactamase producing Enterobacteriaceae in Qatar: A 3-year hospital-based study. *Front. Antibiot.* 1:1-10.
- Amelia, A., Nugroho, A., & Harijanto, P.N., 2016. Diagnosis and Management of Infections Caused by Enterobacteriaceae Producing Extended-Spectrum β -Lactamase. *Acta Med. Indones.* 48(2): 156–166.
- Aslan, A.T., & Akova, M., 2019. Infections caused by extended-spectrum β -lactamase-producing Enterobacteriaceae: clinical and molecular epidemiology and treatment strategies. *Infect. Dis. Clin. Microbiol.* 1(3): 149-157.
- Asmarawati, T.P., Widyatama, F.S., Notobroto, H.B., Nasronudin, N., Sugai, M., *et al.*, 2025. Risk Factors and Clinical Impact of Extended-Spectrum Beta-Lactamase (ESBL)-Producing *Escherichia coli* Bacteremia Among Hospitalized Patients. *Antibiotics* 14(9): 1–17.
- Bahrs, C., 2021. Early Treatment Outcomes for Bloodstream Infections Caused by Potential AmpC Beta-Lactamase-Producing Enterobacterales with Focus on Piperacillin / Tazobactam: A Retrospective Cohort Study. *BMC Infectious Diseases.* 21:1–12.
- Bakthavatchalu, S., Shakthivel, U., & Mishra, T., n.d. 2025. Detection of ESBL among inhibitor-based method ampc producing enterobacteriaceae using *Microb Pathog.* 200: 107275-107285.
- Bhandari, A., Khatiwada, S., Sharma, A., Aryal, S.C., Shrestha, R., *et al.*, 2024. Prevalence of drug resistant Enterobacteriaceae in a Nepalese tertiary care hospital. *PLOS Glob. Public Heal.* 4(1): 1–7.
- Burnham, J.P., & Kollef, M.H., 2018. qSOFA score: Predictive validity in Enterobacteriaceae bloodstream infections. *J. Crit. Care* 43: 1–17.
- Bush, K. & Jacoby, G.A. (2010) Updated functional classification of β -lactamases. *Antimicrobial Agents and Chemotherapy.* ASM. 54(3): 969–976.
- D’Onofrio, V., Cartuyvels, R., Messiaen, P.E.A., Barišić, I., & Gyssens, I.C., 2023. Virulence Factor Genes in Invasive *Escherichia coli* Are Associated with Clinical Outcomes and Disease Severity in Patients with Sepsis: A Prospective Observational Cohort Study. *Microorganisms.* 11: 1827-1843.
- Dat, V.Q., Vu, H.N., Nguyen The, H., Nguyen, H.T., Hoang, L.B., *et al.*, 2017. Bacterial bloodstream infections in a tertiary infectious diseases hospital in Northern Vietnam: Aetiology, drug resistance, and treatment outcome. *BMC Infect. Dis.* 17(1): 1–11.

- Davin-Regli, A., Lavigne, J.P., & Pagès, J.M., 2019. Enterobacter spp.: update on taxonomy, clinical aspects, and emerging antimicrobial resistance. *Clin. Microbiol. Rev.* 32(4):1-32.
- Dias, S.P., Brouwer, M.C., & Van De Beek, D., 2022. Sex and Gender Differences in Bacterial Infections. *Infect. Immun.* 90(10): 1-19.
- Edition, S.C., State, B., State, Kano, & State, Kebbi, 2022. Prevalence of Extended-Spectrum Beta Lactamase and Ampc Producing Enterobacteriaceae Among Diabetic Patients in Bauchi State , Nigeria. *Bayero J. Pure Appl. Sci.* 13(1): 546–553.
- El-Hady, S.A., & Adel, L.A., 2015. Occurrence and detection of AmpC β -lactamases among Enterobacteriaceae isolates from patients at Ain Shams University Hospital. *Egypt. J. Med. Hum. Genet.* 16(3): 239–244.
- Elawady, B.A., Mahmoud, N.R., Badawi, H.E.S., Badr, A.E.E., & Gohar, N.M., 2024. Antimicrobial activity of cefepime-tazobactam combination against extended spectrum beta-lactamase and/or AmpC beta-lactamase- producing gram-negative bacilli. *BMC Infect. Dis.* 24(1): 1–9.
- Estaleva, C.E.L., Zimba, T.F., Sekyere, J.O., Govinden, U., Chenia, H.Y., *et al.*, 2021. High prevalence of multidrug resistant ESBL- and plasmid mediated AmpC-producing clinical isolates of Escherichia coli at Maputo Central Hospital, Mozambique. *BMC Infect. Dis.* 21(1): 1–6.
- Etemadi, S., Ebrahimzadeh Leylabadlo, H., & Ghotaslou, R., 2020. AmpC β -lactamase among Enterobacteriaceae: A new insight. *Gene Reports.* 19: 1-19.
- Fernando, S.M., Rochweg, B., & Seely, A.J.E., 2018. Clinical implications of the third international consensus definitions for sepsis and septic shock (Sepsis-3). *Cmaj* 190(36): E1058–E1059.
- Flores-mireles, A.L., Walker, J.N., Caparon, M., & Hultgren, S.J., 2016. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. *Nat Rev Microbiol.* 13(5): 269–284.
- Fröding, I., Hasan, B., Sylvin, I., Coorens, M., Naucélér, P., *et al.*, 2020. Extended-Spectrum- β -Lactamase- and Plasmid AmpC-Producing Escherichia coli Causing Community-Onset Bloodstream Infection: Association of Bacterial Clones and Virulence Genes with Septic Shock, Source of Infection, and Recurrence. *Antimicrob. Agents Chemother.* 64(8): 1–17.
- Ghotaslou, R., Sadeghi, M.R., Akhi, M.T., Hasani, A., & Asgharzadeh, M., 2018. Prevalence and antimicrobial susceptibility patterns of ESBL, ampC and carbapenemase-producing enterobacteriaceae isolated from hospitalized patients in Azerbaijan, Iran. *Iran. J. Pharm. Res.* 17: 79–88.
- Grover, N., Sahni, A.K., & Bhattacharya, S., 2013. Therapeutic challenges of ESBLs and Ampc beta-lactamase producers in a tertiary care center. *Med. J. Armed Forces India* 69(1): 4–10.

- Gupta, G., Tak, V., & Mathur, P., 2014. Detection of AmpC β Lactamases in Gram-negative Bacteria. *J. Lab. Physicians*. 6(01): 001-006.
- Guzmán-Blanco, M., Labarca, J.A., Villegas, M.V., & Gotuzzo, E., 2014. Extended spectrum β -lactamase producers among nosocomial Enterobacteriaceae in Latin America. *Brazilian J. Infect. Dis.* 18(4): 421–433.
- Hafiz, T.A., Alghamdi, G.S., Alkudmani, Z.S., Alyami, A.S., Almazyed, A., *et al.*, 2024. Multidrug-Resistant *Proteus mirabilis* Infections and Clinical Outcome at Tertiary Hospital in Riyadh , Saudi Arabia. *Infect Drug Resist.* 17: 571–581.
- Harris, P.N.A., 2015. Clinical management of infections caused by enterobacteriaceae that express extended-spectrum β -Lactamase and AmpC enzymes. *Semin. Respir. Crit. Care Med.* 36(1): 56–73.
- Holmes, C.L., Anderson, M.T., Mobley, H.L.T., & Bachman, M.A., 2021. Pathogenesis of Gram-Negative Bacteremia. *Clin. Microbiol. Rev.* 34(2): 234–261.
- Hu, Y.J., Ogyu, A., Cowling, B.J., Fukudaa, K., & Panga, H., 2019. Available evidence of antibiotic resistance from extended-spectrum β -lactamase-producing enterobacteriaceae in paediatric patients in 20 countries: A systematic review and meta-analysis. *Bull. World Health Organ.* 97(7): 486–501B.
- Husna, A., Rahman, M.M., Badruzzaman, A.T.M., Sikder, M.H., Islam, M.R., *et al.*, 2023. Extended-Spectrum β -Lactamases (ESBL): Challenges and Opportunities. *Biomedicines* 11(11): 1-22.
- Iqbal, M.J., Islam, M.A., Sen, T., Modak, B., & Ghosh, K., 2025. Clinical and Etiological Patterns of Urinary Tract Infections in Children. *J Lab Physicians*. 08(01): 138–142.
- Irvan, F.S., 2018. Sepsis dan Tatalaksana Berdasar Guideline Terbaeu. *J. Anesthesiol. Indones.* X(1): 62–73.
- Jacobsen, S.M., Stickler, D.J., Mobley, H.L.T., & Shirtliff, M.E., 2008. Complicated Catheter-Associated Urinary Tract Infections Due to *Escherichia coli* and *Proteus mirabilis*. *ASM.* 21(1): 26–59.
- Kang, C., Song, J., Ryeon, D., Ran, K., Soo, K., *et al.*, 2010. Risk factors and treatment outcomes of community-onset bacteraemia caused by extended-spectrum β -lactamase-producing *Escherichia coli* Chisook Moon m , Sang Yop Shin n , on behalf of the Korean Network. *Int J Antimicrob Agents.* 36: 284–287.
- Kingren, M.S., Starr, M.E., & Saito, H., 2021. Divergent Sepsis Pathophysiology in Older Adults. *Antioxid Redox Signal.* 35(16): 1358–1375.
- Kolář, M., 2018. Antibiotic treatment of infections caused by atypical bacteria. *Interní medicína pro praxi.* 20(1): 1–17.

- Laih, C.Y., Hsiao, P.J., Hsieh, P.F., Wang, Y. De, Lai, C.M., *et al.*, 2022. QSOFA and SOFA scores are valuable tools for predicting postoperative sepsis resulting from ureteroscopic lithotripsy (URSL). *Med.* 101(50): 1-6.
- Leekha, S., Terrell, C.L., & Edson, R.S., 2011. General Principles of Antimicrobial Therapy. *Mayo Clin Proc.* 86(2): 156–167.
- Legese, M.H., Asrat, D., Aseffa, A., Hasan, B., Mihret, A., *et al.*, 2022. Molecular Epidemiology of Extended-Spectrum Beta-Lactamase and AmpC Producing Enterobacteriaceae among Sepsis Patients in Ethiopia: A Prospective Multicenter Study. *Antibiotics.* 11(2): 131- 149.
- Leverstein-van Hall, M.A., Fluit, A.C., Paauw, A., Box, A.T.A., Brisse, S., *et al.*, 2002. Evaluation of the Etest ESBL and the BD Phoenix, VITEK 1, and VITEK 2 automated instruments for detection of extended-spectrum beta-lactamases in multiresistant *Escherichia coli* and *Klebsiella* spp. *J. Clin. Microbiol.* 40(10): 3703–3711.
- Li, X., & Ye, H., 2017. Clinical and mortality risk factors in bloodstream infections with carbapenem-resistant enterobacteriaceae. *Can. J. Infect. Dis. Med. Microbiol.* 2017: 1-5.
- Liana, P., Chahril, N.B., Nita, S., & Umar, T.P., 2022. Prevalence of Extended-Spectrum Beta Lactamase-Producing Microorganisms in Dr. Mohammad Hoesin Hospital Palembang. *Indones. J. Clin. Pathol. Med. Lab.* 28(3): 263–268.
- Lim, C.L., & Spelman, D., 2019. Mortality impact of empirical antimicrobial therapy in ESBL- and AmpC-producing Enterobacteriaceae bacteremia in an Australian tertiary hospital. *Infect. Dis. Heal.* 24(3): 124–133.
- Ling, W., Paterson, D.L., Harris, P.N.A., Furuya-Kanamori, L., Edwards, F., *et al.*, 2024. Mortality, hospital length of stay, and recurrent bloodstream infections associated with extended-spectrum beta-lactamase-producing *Escherichia coli* in a low prevalence region: A 20-year population-based large cohort study. *Int. J. Infect. Dis.* 138: 84–90.
- Magliano, E., Grazioli, V., Deflorio, L., Leuci, A.I., Mattina, R., *et al.*, 2012. Gender and age-dependent etiology of community-acquired urinary tract infections. *Sci. World J.* 2012: 1-6.
- Mahdani, W., Albela, A., Hayati, Z., & Suhartono, S., 2024. Prevalence of extended spectrum beta-lactamase (ESBL) *Escherichia coli* recovered from ICU and non-ICU at dr. Zainoel Abidin General Hospital. *BIO Web Conf.* 94: 1–8.
- Mandal, D.K., Sah, S.K., Mishra, S.K., Sharma, S., Kattel, H.P., *et al.*, 2020. Carriage of Extended-Spectrum- β -Lactamase- And AmpC- β -Lactamase-Producing Enterobacteriaceae (ESBL-PE) in Healthy Community and Outpatient Department (OPD) Patients in Nepal. *Can. J. Infect. Dis. Med. Microbiol.* 2020: 1-9.

- Mansouri, S., Savari, M., Malakian, A., & Abbasi Montazeri, E., 2024. High prevalence of multidrug-resistant Enterobacterales carrying extended-spectrum beta-lactamase and AmpC genes isolated from neonatal sepsis in Ahvaz, Iran. *BMC Microbiol.* 24(1): 1–11.
- Masterton, R.G., 2011. Antibiotic De-Escalation. *Crit. Care Clin.* 27(1): 149–162.
- Mirzaei, B., Babaei, R., Bazgir, Z.N., Goli, H.R., Keshavarzi, S., *et al.*, 2021. Prevalence of Enterobacteriaceae spp. and its multidrug-resistant rates in clinical isolates: A two-center cross-sectional study. *Mol. Biol. Rep.* 48(1): 665–675.
- Modi, D.J., Patel, B. V, Patel, M.H., Bhatt, S.S., Sood, N.K., *et al.*, 2012. A study of Extended Spectrum beta -Lactamase (ESBL) and AmpC beta -Lactamase producing *Klebsiella pneumoniae* in Neonatal Intensive Care Unit at Tertiary Care Hospital, Ahmedabad. *Natl. J. Community Med.* 3: 523–528.
- Mohamed, E.S., Khairy, R.M.M., & Abdelrahim, S.S., 2020. Prevalence and molecular characteristics of ESBL and AmpC β -lactamase producing Enterobacteriaceae strains isolated from UTIs in Egypt. *Antimicrob. Resist. Infect. Control.* 9(1): 1–9.
- Mohamed Shukri, N.R.I., Hassan, S.K., Md Noor, S.S., Ab Hamid, S.A., Nik Mohamad, N.A., *et al.*, 2024. The Outcome of Hospital-Acquired Bloodstream Infection and Its Associated Factors in Critical Care Unit. *Malaysian J. Med. Sci.* 31(6): 160–177.
- Mol P, R., Bindayna, K.M., & Shanthi, G., 2021. Evaluation of Two Phenotypic Methods for the Detection of Plasmid-Mediated AmpC β -Lactamases among Enterobacteriaceae Isolates. *J. Lab. Physicians.* 13(2): 151–155.
- Morales-López, S., Yepes, J.A., Prada-Herrera, J.C., & Torres-Jiménez, A., 2019. Enterobacteria in the 21st century: A review focused on taxonomic changes. *J. Infect. Dev. Ctries.* 13(4): 265–273.
- Mounier, R., Guen, R. Le, Woerther, P.L., Nacher, M., Bonnefon, C., *et al.*, 2022. Clinical outcome of wild - type AmpC - producing Enterobacterales infection in critically ill patients treated with β - lactams : a prospective multicenter study. *Ann. Intensive Care.* 12:1–12.
- Mulvey, M.A., 2002. Adhesion and entry of uropathogenic *Escherichia coli*. *Cell. Microbiol.* 4(5): 257–271.
- Namikawa, H., Yamada, K., Fujimoto, H., Oinuma, K.I., Tochino, Y., *et al.*, 2017. Clinical characteristics of bacteremia caused by extended-spectrum beta-lactamase-producing *Escherichia coli* at a tertiary hospital. *Intern. Med.* 56(4): 1807–1815.
- Nasrollahian, S., Graham, J.P., & Halaji, M., 2024. A review of the mechanisms that confer antibiotic resistance in pathotypes of *E. coli*. *Front. Cell. Infect. Microbiol.* 14: 1–28.

- Naushad, V.A., Purayil, N.K., Wilson, G.J., Chandra, P., Joseph, P., *et al.*, 2022. Epidemiology of urinary tract infection in adults caused by extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae – a case-control study from Qatar. *IJID Reg.* 3: 278–286.
- Ndir, A., Diop, A., Faye, P.M., Cissé, M.F., Ndoye, B., *et al.*, 2016. Epidemiology and burden of bloodstream infections caused by extended-spectrum beta-lactamase producing enterobacteriaceae in a Pediatric Hospital in Senegal. *PLoS One.* 11(2): 1–13.
- Oberoi, L., Singh, N., Sharma, P., & Aggarwal, A., 2013. ESBL, MBL and Ampc β lactamases producing superbugs - Havoc in the intensive care units of Punjab India. *J. Clin. Diagnostic Res.* 7(1):70–73.
- Park, Y.S., Yoo, S., Seo, M.R., Kim, J.Y., Cho, Y.K., *et al.*, 2009. Risk factors and clinical features of infections caused by plasmid-mediated AmpC β -lactamase-producing Enterobacteriaceae. *Int. J. Antimicrob. Agents.* 34(1): 38–43.
- Paterson, D.L., 2006. Resistance in Gram-Negative Bacteria: Enterobacteriaceae. *Am. J. Med.* 119(6): 20–28.
- Peter, J.A., Masoud, S., Kamori, D., Joachim, A., Kibwana, U., *et al.*, 2025. Co-occurrence and importance of AmpC and extended-spectrum beta-lactamases-producing gram-negative bacilli in clinical specimens at a Tertiary Hospital in Dar es Salaam, Tanzania. *Bull. Natl. Res. Cent.* 49(1):1–10.
- Piérard, D., Hermsen, E.D., Kantecki, M., & Arhin, F.F., 2023. Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents against Enterobacterales Analyzed by ICU and Non-ICU Wards, Infection Sources, and Geographic Regions: ATLAS Program 2016–2020. *Antibiotics.* 12(11) : 1-27.
- Pitout, J.D.D., & Deviney, R., 2017. Escherichia coli ST131 : a multidrug-resistant clone primed for global domination [version 1 ; referees : 2 approved] Referee Status. *F1000Res.* 6: 1–7.
- Polsfuss, S., Bloemberg, G. V., Giger, J., Meyer, V., Böttger, E.C., *et al.*, 2011. Practical approach for reliable detection of AmpC beta-lactamase-producing Enterobacteriaceae. *J. Clin. Microbiol.* 49(8): 2798–2803.
- Pospišil, M., Car, H., Elvedić-Gašparović, V., Beader, N., Herljević, Z., *et al.*, 2023. Bloodstream Infections by AmpC-Producing Enterobacterales: Risk Factors and Therapeutic Outcome. *Pathogens* 12(9): 1-15.
- Raphael, E., Glymour, M.M., & Chambers, H.F., 2021. Trends in prevalence of extended-spectrum beta-lactamase-producing Escherichia coli isolated from patients with community- and healthcare-associated bacteriuria: results from 2014 to 2020 in an urban safety-net healthcare system. 2021 *Antimicrob. Resist. Infect. Control.* 10(1): 118-134.
- Rastely-Junior, V.N., Rocha, H.S.N., & Reis, M.G., 2025. AmpC β -Lactamase-

- Producing Microorganisms in South American Hospitals: A Meta-Regression Analysis, Meta-Analysis, and Review of Prevalence. *Trop. Med. Infect. Dis.* 10(10): 280-305
- Rawat, V., Singhai, M., & Verma, P.K., 2020. Detection of Different β -Lactamases and their Co-existence by Using Various Discs Combination Methods in Clinical Isolates of Enterobacteriaceae and Pseudomonas spp. *J Lab Physicians.* 5(1): 21–25.
- Ray, S.M., Thompson, D.L., & Wilson, L.E., Multistate Point-Prevalence Survey of Health Care–Associated Infections. 2015. *N Engl J Med.* 370(13): 1198–1208.
- Rensing, K.L., Abdallah, H.M., Koek, A., Elmowalid, G.A., Vandenbroucke-Grauls, C.M.J.E., *et al.*, 2019. Prevalence of plasmid-mediated AmpC in Enterobacteriaceae isolated from humans and from retail meat in Zagazig, Egypt. *Antimicrob. Resist. Infect. Control.* 8(1): 1–8.
- Rhee, C., Dantes, R., Epstein, L., Murphy, D.J., Seymour, C.W., *et al.*, 2017. Incidence and Trends of Sepsis in US Hospitals Using Clinical vs Claims Data, *JAMA.* 02215: 1-9.
- Rodriguez-Baño, J., Gutiérrez-Gutiérrez, B., Machuca, I., & Pascual, A., 2018. Treatment of Infections Caused by Extended-Spectrum-Beta-. *Clin. Microbiol. Rev.* 31(2): 1–42.
- Romyasamit, C., Sornsenee, P., Kawila, S., & Saengsuwan, P., 2024. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: insights from a tertiary hospital in Southern Thailand . *Microbiol. Spectr.* 12(7): 1–12.
- Ruh, E., Zakka, J., Hoti, K., Fekrat, A., Guler, E., *et al.*, 2019. Extended-spectrum β -lactamase, plasmid-mediated AmpC β -lactamase, fluoroquinolone resistance, and decreased susceptibility to carbapenems in Enterobacteriaceae: Fecal carriage rates and associated risk factors in the community of Northern Cyprus. *Antimicrob. Resist. Infect. Control.* 8(1): 1–10.
- Russo, A., Falcone, M., Gutiérrez-Gutiérrez, B., Calbo, E., Almirante, B., *et al.*, 2018. Predictors of outcome in patients with severe sepsis or septic shock due to extended-spectrum β -lactamase-producing Enterobacteriaceae. *Int. J. Antimicrob. Agents.* 52(5): 577-585.
- Saffar, H., Niaraki, N.A., Tali, A.G., Baseri, Z., Abdollahi, A., *et al.*, 2016. Prevalence of AmpC β -lactamase in clinical isolates of Escherichia coli, Klebsiella spp., and Proteus mirabilis in a tertiary hospital in Tehran, Iran. *Jundishapur J. Microbiol.* 9(12): 1–6.

- Saleh, Z. M., Umar, A. T., Baba, F. A., Adamu, M. T., Yarma, A. A., *et al.*, 2024. Prevalence of Enterobacteriaceae from Clinical Isolates in Federal Teaching Hospital Gombe, Nigeria. *UMYU J. Microbiol. Res.* 9(1): 258–264.
- Schoevaerdt, D., Bogaerts, P., Grimmelprez, A., de Saint-Hubert, M., Delaere, B., *et al.*, 2011. Clinical profiles of patients colonized or infected with extended-spectrum beta-lactamase producing Enterobacteriaceae isolates: A 20 month retrospective study at a Belgian University Hospital. *BMC Infect. Dis.* 11(12): 1-10.
- Schwaber, M.J., & Carmeli, Y., 2007. Mortality and delay in effective therapy associated with extended-spectrum β -lactamase production in Enterobacteriaceae bacteraemia: A systematic review and meta-analysis. *J. Antimicrob. Chemother.* 60(5): 913–920.
- Shaaban, M., Elshaer, S.L., & Abd El-Rahman, O.A., 2022. Prevalence of extended-spectrum β -lactamases, AmpC, and carbapenemases in *Proteus mirabilis* clinical isolates. *BMC Microbiol.* 22(1): 1–13.
- Shiferaw Teklu, D., Hailu Legese, M., Eshetu, K., Aseffa Negeri, A., Fentaw, S., *et al.*, 2019. Comparison of Double Disk Synergy Test and Combination Disk Test Methods for the Detection of Extended-Spectrum Beta-Lactamase Production among Enterobacteriaceae. *EC Microbiol.* 16(6): 411–420.
- Soekoyo, A.R., Sulistiawati, S., Setyorini, W., & Kuntaman, K., 2020. The Epidemiological Pattern and Risk Factor of ESBL (Extended Spectrum B-Lactamase) Producing Enterobacteriaceae in Gut Bacterial Flora of Dairy Cows and People Surrounding in Rural Area, Indonesia. *Indones. J. Trop. Infect. Dis.* 8(3): 144-151.
- Soltani, E., Hasani, Alka, Rezaee, M.A., Pirzadeh, T., Oskouee, M.A., *et al.*, 2020. Virulence characterization of *klebsiella pneumoniae* and its relation with ESBL and AMPC beta-lactamase associated resistance. *Iran. J. Microbiol.* 12(2): 98–106.
- Soni, J., Sinha, S., & Pandey, R., 2024. Understanding bacterial pathogenicity: a closer look at the journey of harmful microbes. *Front. Microbiol.* 15(1): 1-14.
- Stankova, P., Boyanova, L., Atanasova, D., Mihaylova, S., Sredkova, M., *et al.*, 2024. Extended-Spectrum Beta-Lactamase- and Plasmidic AmpC-Producing Enterobacteriales among the Faecal Samples in the Bulgarian Community. *Microorganisms* 12: 1-15.
- Suhartono, S., Mahdani, W., & Khalizazia, K., 2022. Prevalence and Antibiotic Susceptibility of *Proteus mirabilis* Isolated from Clinical Specimens in the Zainoel Abidin General Hospital, Banda Aceh, Indonesia. *Open Access Maced. J. Med. Sci.* 10(A): 1532–1537.

- Tadesse, S., Mulu, W., Genet, C., Kibret, M., & Belete, M.A., 2022. Emergence of High Prevalence of Extended-Spectrum Beta-Lactamase and Carbapenemase-Producing Enterobacteriaceae Species among Patients in Northwestern Ethiopia Region. *Biomed Res. Int.* 2022:1-9.
- Tamma, P.D., Doi, Y., Bonomo, R.A., Johnson, J.K., & Simner, P.J., 2019. A Primer on AmpC β -Lactamases: Necessary Knowledge for an Increasingly Multidrug-resistant World. *Clin. Infect. Dis.* 69(8):1446–1455.
- Tamma, P.D., Han, J.H., Rock, C., Harris, A.D., Lautenbach, E., *et al.*, 2015. Carbapenem Therapy Is Associated With Improved Survival Compared With Piperacillin- Tazobactam for Patients With Extended- Spectrum β -Lactamase Bacteremia. *Clin Infect Dis.* 60: 1319–1325.
- Tamma, P.D., & Villegas, M.V., 2017. Use of β -Lactam/ β -Lactamase Inhibitors for Extended-Spectrum- β -Lactamase Infections: Defining the Right Patient Population. *Antimicrob. Agents Chemother.* 61(8): 1-3.
- Tian, H., Zhou, J., Weng, L., Hu, X., Peng, J., *et al.*, 2019. Accuracy of qSOFA for the diagnosis of sepsis-3: A secondary analysis of a population-based cohort study. *J. Thorac. Dis.* 11(5): 2034–2042.
- Tilahun, M., Kassa, Y., Gedefie, A., & Ashagire, M., 2021. Emerging carbapenem-resistant enterobacteriaceae infection, its epidemiology and novel treatment options: A review. *Infect. Drug Resist.* 14: 4363–4374.
- Ting, S.M.V., Ismail, Z., & Hanafiah, A., 2024. Prevalence of AmpC beta-lactamase and extended spectrum beta-lactamase co-producer in *Escherichia coli* and *Klebsiella* species in a teaching hospital. *Malays. J. Pathol.* 46(1): 79–89.
- Van den Bunt, G., Liakopoulos, A., Mevius, D.J., Geurts, Y., Fluit, A.C., *et al.*, 2017. ESBL/AmpC-producing Enterobacteriaceae in households with children of preschool age: Prevalence, risk factors and co-carriage. *J. Antimicrob. Chemother.* 72(2): 589–595.
- Vance, M.K., Cretella, D.A., Ward, L.M., Vijayvargiya, P., Garrigos, Z.E., *et al.*, 2023. Risk Factors for Bloodstream Infections Due to ESBL-Producing *Escherichia coli*, *Klebsiella* spp., and *Proteus mirabilis*. *Pharmacy* 11(2): 1-12.
- Vázquez-Martínez, E.R., García-Gómez, E., Camacho-Arroyo, I., & González-Pedrajo, B., 2018. Sexual dimorphism in bacterial infections. *Biol. Sex Differ.* 9: 1–20.
- Wang, X., Guo, Z., Chai, Y., Wang, Ziyi, Liao, H., *et al.*, 2023. Application Prospect of the SOFA Score and Related Modification Research Progress in Sepsis. *J. Clin. Med.* 12(10): 1-15.
- Wen, H., Xie, S., Liu, Y., Liang, Y., Zhang, P., *et al.*, 2023. Retrospective Analysis

of Sensitivity Characteristics of Enterobacteriaceae: A Study Based on Specimen Types, Sex, and Age Bracket of Patients. *Infect. Drug Resist.* 16: 1753–1765.

Wu, D., Xiao, J., Ding, J., Jia, Y., & Guo, Z., 2021. Predictors of Mortality and Drug Resistance Among Carbapenem-Resistant Enterobacteriaceae -Infected Pancreatic Necrosis Patients. *Infect Dis Ther.*10:1665–1676.

Yen, C.S., Hsiao, H.L., Lee, C.C., Tsai, T.C., Chen, H.Y., *et al.*, 2023. Carbapenem-resistant Enterobacteriaceae infection in children less than one year old in an Asian medical center. *Pediatr. Neonatol.* 64(2): 168–175.

Yoo, E.H., Hong, H.L., & Kim, E.J., 2023. Epidemiology and Mortality Analysis Related to Carbapenem-Resistant Enterobacteriales in Patients After Admission to Intensive Care Units: An Observational Study. *Infect. Drug Resist.* 16: 189–200.

Zhou, Y., Zhou, Z., Zheng, L., Gong, Z., Li, Y., *et al.*, 2023. Urinary Tract Infections Caused by Uropathogenic Escherichia coli: Mechanisms of Infection and Treatment Options. *Int. J. Mol. Sci.* 24:1-33.